Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vera Therapeutics, Inc.

21.31
-1.4300-6.29%
Post-market: 21.310.00000.00%16:20 EDT
Volume:1.28M
Turnover:27.10M
Market Cap:1.36B
PE:-7.75
High:22.18
Open:22.18
Low:20.27
Close:22.74
Loading ...

Company Profile

Company Name:
Vera Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
- -
Office Location:
2000 Sierra Point Parkway,Suite 1200,Brisbane,California,United States
Zip Code:
94005
Fax:
- -
Introduction:
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Directors

Name
Position
Marshall Fordyce
President, Chief Executive Officer and Director
Kurt von Emster
Chairperson of the Board
Andrew Cheng
Director
Beth Seidenberg
Director
Maha Katabi
Director
Patrick Enright
Director
Scott Morrison
Director

Shareholders

Name
Position
Marshall Fordyce
President, Chief Executive Officer and Director
Jonathan Wolter
Chief Financial Officer
Celia Lin
Chief Medical Officer
Joanne Curley
Chief Development Officer